Wang Haiping: two vote system is a historic opportunity for pharmaceutical B2B industry

Source: Wang Haiping, chairman of Xinkangjie 2016-06-29 star B2B enterprise yaoyaohao, has been busy recently "The pharmaceutical companies that were still waiting have taken the initiative to talk about cooperation." There are many famous joint ventures and foreign-funded enterprises coming to discuss cooperation Why? Two vote system! Among the medical policies in 2016, the "two vote system" which is intended to control the price rise of drugs is the most concerned one Based on the original Anhui, Fujian, Jiangsu and Qinghai pilot provinces, the two vote pilot provinces have now expanded to 11 provinces including Zhejiang, Hunan and Sichuan The implementation of the two vote system, from production to circulation, shocks the whole industry The great reshuffle of medicine circulation industry is coming But what Wang Haiping smelled was that "the historic opportunity for B2B enterprises has come." Because, "B2B is a two vote system." In 2016, the target is 3.5 billion yuan Last year, the online revenue of HaoChun pharmacy was 1 billion yuan Although its headquarters in East China accounted for 50% of the total, the speed of its national layout is still impressive: in terms of terminals, the cooperative drugstores involved 30 provinces and cities, 130000 registered drugstores, and about 80000 active drugstores; in the upstream, it reached cooperation with more than 2000 pharmaceutical factories, nearly 1000 Family has formed close cooperation This year, the goal of good medicine is 3 billion 500 million yuan However, Wang Haiping said that he did not like to de localize data "We can talk about specific data in one year or two years, but it is impossible to localize data in three years or five years." He said it was "plain muddle" Where is it clear? How can we tolerate muddleheaded? According to Wang Haiping, the model must be clear, but there must be unpredictable obstacles to the progress of the curve in the process By analyzing the model of good medicine and medicine, we can find that its structure logic is not complicated: the core of B2B platform, access to value-added services such as data and finance, get through the flow of goods, information and technology, and achieve index level development by entering the capital market B2B is not to subvert the upstream and downstream, reduce three or even more than seven layers of agents in the middle The goal of B2B is to achieve direct access from the pharmaceutical factory to the terminal, which can be said to be one of the best ways to realize the two vote system promoted by the current policy However, China's market is so large that even big business enterprises such as Sinopharm, China Resources and kyushutong are still difficult to achieve full coverage How far can a B2B enterprise officially launched for less than two years trigger a subversive change in the distribution pattern? Only by Wang Haiping as a historical opportunity of the two vote system, part of the industry has expressed concern about local monopoly Many voices pointed out that due to the objective existence of logistics and other practical problems, the two ticket system has become a trend of increasing local protection and monopoly However, Wang Haiping corrected the saying of "subversion" He believes that pharmaceutical B2B is not subversion, just like the subversion theory at the beginning of the rise of pharmaceutical B2C, it actually ignores the biased view of the particularity of the pharmaceutical industry Now it can be seen clearly that B2C of medicine has encountered a bottleneck, and o2o, which integrates online and offline, is in the ascendant In the same way, any pharmaceutical B2B platform is a castle in the air, let alone a subversion, when it leaves the offline commercial circulation channel to talk about development "Increasing concentration is the trend, and the reshuffle is inevitable, but B2B enterprises still need to maximize cooperation with high-quality offline commercial enterprises." Wang Haiping pointed out But that doesn't stop the medicine from being as good as it can be The reason is simple, because it has no burden Now, about half of the team of yaoyaohao 300 is technology and half is operation That is to say, there are senior medical operators from traditional commercial enterprises They have also formed their own core technology team and completed the grafting and fusion of medical gene and Internet gene The vipshop B2B in medicine B2B, from once considered as "nonexistent mode" to now "good business" which makes all the big people eager to do, has been a undercurrent in just a few years According to CFDA data, as of the beginning of June 2016, there were 135 b-cards in China, and B2B enterprises' actions were also frequent For example, Zhencheng medicine put into Kangenbei's arms online, and Jingdong cooperated with Shanghai Pharmaceutical to launch "Shanghai cloud health" However, for the time being, there are few platforms forming influence and absolute advantage nationwide From industry, commerce to terminal, good pharmaceutical partners have extended to all links of the industrial chain, which can be said to make a model in the vertical field of pharmaceutical e-commerce In an interview with the overseas edition of the people's daily at the beginning of this year, Wang Haiping mentioned that B2B has compressed the layers of agents that are too long, too many and too disorderly in the industrial chain, reducing the drug price by about 30%, benefiting the country, the people and the enterprises However, from the standpoint of enterprises, drug price reduction itself is a controversial topic, which involves the balance of interests of all parties "What medicine is good for is the only club in the pharmaceutical industry." Wang Haiping said In his opinion, this can directly explain the problem of interest balance between good medicine and various links of the industrial chain First of all, the products of thousands of pharmaceutical enterprises all over the country can find corresponding positions on the platform of good medicine "The first is the best-selling products in the region, and we will enhance their market share by quantitative cooperation; the second is the specification differentiation cooperation; the third is to activate the" dormant products "in brand enterprises." Secondly, the above cooperation with pharmaceutical companies comes from their coverage of pharmaceutical retail terminals, and the cooperation with pharmaceutical retail terminals will also be layered Large scale chain agent products also have the possibility of cooperation with Yaohao, while regional representative chains will develop together with interest alliance cooperation For commercial wholesalers, Pharma will take advantage of the platform advantages, tap the potential of offline commercial wholesalers, and carry out multi-dimensional cooperation in products, services and distributors